The Directors recognise the importance of good corporate governance and have chosen to apply the Quoted Companies Alliance Corporate Governance Code (the 'QCA Code').
The underlying principle of the QCA code is that "the purpose of good corporate governance is to ensure that the company is managed in an efficient, effective and entrepreneurial manner for the benefit of all shareholders over the longer term".
To see how the Company addresses the key governance principles defined in the QCA Code, please refer to the Corporate Governance Report, on pages 54-57 of the Annual Report or available here.
The list of matters reserved to the Board is available here.
This disclosure was last reviewed and updated on 29 June 2020.
The Board of Directors meets on a regular basis to review key operational issues, strategic development and the financial performance of the Company. The Board undertakes to represent the intentions of shareholders, investors and key stakeholders. The Board is responsible for internal controls to minimise the risk of financial or operational loss or material misstatement. The list of matters reserved to the Board is available here.
The composition of the board is designed to ensure Advanced Oncotherapy has robust and relevant experience from a technology and commercial perspective for a medical device company. The Directors' backgrounds and experiences cover areas of commercial and business development, financial management and control. The full composition of the Board is available here.
The following committees have been established to deal with specific aspects of the Company's affairs, in addition to the usual internal control procedures to govern its routine business activities.
Chairman: Hans von Celsing
Members: Michael Bradfield, Enrico Vanni
Terms of Reference